LTP Stock Overview
LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia, and the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
LTR Pharma Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.26 |
52 Week High | AU$0.41 |
52 Week Low | AU$0.25 |
Beta | 0 |
1 Month Change | -10.53% |
3 Month Change | -22.73% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -32.89% |
Recent News & Updates
Recent updates
Shareholder Returns
LTP | AU Pharmaceuticals | AU Market | |
---|---|---|---|
7D | -8.9% | -2.2% | 0.03% |
1Y | n/a | 26.8% | 4.2% |
Return vs Industry: Insufficient data to determine how LTP performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LTP performed against the Australian Market.
Price Volatility
LTP volatility | |
---|---|
LTP Average Weekly Movement | 11.1% |
Pharmaceuticals Industry Average Movement | 10.7% |
Market Average Movement | 9.0% |
10% most volatile stocks in AU Market | 17.7% |
10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: LTP's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine LTP's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | n/a | n/a | www.ltrpharma.com |
LTR Pharma Limited, a biopharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia, and the United States. Its lead product candidate is SPONTAN, an intranasal delivery technology for safe and effective oral PDE5 inhibitor and vardenafil HCL. LTR Pharma Limited was incorporated in 2020 and is based in Brisbane, Australia.
LTR Pharma Limited Fundamentals Summary
LTP fundamental statistics | |
---|---|
Market cap | AU$35.55m |
Earnings (TTM) | AU$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs LTP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LTP income statement (TTM) | |
---|---|
Revenue | AU$0 |
Cost of Revenue | AU$0 |
Gross Profit | AU$0 |
Other Expenses | AU$0 |
Earnings | AU$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did LTP perform over the long term?
See historical performance and comparison